- Bomtech Electronics Co., Ltd. v. MT. Derm, (E.D.N.Y. and PTAB): Representation of Bomtech in Inter Partes Review to invalidate patents on permanent make-up devices, where the case ended with a favorable settlement following institution of the IPR proceeding
Kisuk Lee
Kisuk serves as intellectual property counsel to leading domestic and international pharmaceutical, life science, biotechnology, mechanical and chemical arts focused organizations. Large and small companies alike turn to Kisuk to protect their most valuable R&D investments and innovations. He knows first-hand what it takes to safeguard and leverage such complex assets in today’s global marketspace.
Kisuk is involved patent prosecution, as well as in the preparation of legal opinions including patentability, infringement, freedom to operate, patent landscaping and licensing. He also prepares opinions regarding the Hatch-Waxman Act, including Paragraph IV certifications for ANDA and FDA Orange Book listings. Kisuk offers significant experience in global IP portfolio management and due diligence assessments. His experience, however, is not limited to patents only, and also includes legal advice pertaining to trademarks, trade dress, trade secrets and copyrights.
In the News
- Harness IP Team Secures Favorable Client Outcome In Trademark Case
- Harness IP’s Kisuk Lee Answers Questions for Bio Pharm International Regarding SCOTUS’ Amgen v. Sanofi Patent Decision
PRESENTATIONS
- Speaker at BIO KOREA 2017 International Convention on U.S. IP Strategy for Digital Healthcare
- Speaker at BIO KOREA 2016 International Convention on U.S. Pharma IP Licensing
Articles
- Kisuk Lee Quoted in Law360 Article Discussing Recent USPTO Decision Regarding Antibody Patent Claims
- "What Innovators Can Expect In The Patent World After Amgen" Law360
- “From FTC to SCOTUS, Amgen’s Woes are Potential ‘Game Changers’ for the Industry” PharmaVoice
- “US Supreme Court Weighs Biologics Patents in Amgen vs. Sanofi Case,” PharmTech and BioPharm International
- “Lawmakers Press FDA on Clinical Trial Holds,” Politico
- “SCOTUS to Decide ‘Fundamental Change’ in Biologics Patents with Fate of Amgen v. Sanofi,” PharmaVoice
Blogs
- U.S. Chemical & Life Science Patents Q2 Newsletter
- Enablement, Anticipation, and Claim Strategy: Rethinking Biotech Patent Drafting Post-Agilent
- Routine Optimization Does Not Necessarily Require a Disclosure of Ranges Under the Results-effective Variable Doctrine - Pfizer v. Sanofi, No. 19-1871 (Fed Cir 2024)
- “Pharma IP Due Diligence,” Korean Drug Development Fund Newsletter (KDDF is a governmental organization supporting Korean companies developing new drugs), November 3, 2014
Before joining Harness IP, Kisuk worked as a Korean patent attorney involved in a variety of international patent issues. In patent prosecution and litigation cases, he successfully represented several multi-national companies in the development of new medicines and chemicals. As a result, Kisuk is particularly adept at understanding the cultural and commercial needs of both U.S. and Asian-Pacific companies.
While in law school, Kisuk worked for Pfizer, where he handled major projects related to drug patent management and prosecution. While earning his master’s degree, Kisuk studied molecular biology; in particular, the mechanisms of cell signaling and genetic diseases in support of the prosecution of patents for commercial drugs.
Memberships
- American Intellectual Property Law Association (AIPLA)
- Korean Patent Attorneys Association (KPAA), U.S. Reporter, Patent and Trademark newsletter
Languages
- Korean, native proficiency
- Japanese, professional working proficiency
Direct: 314.446.7670
Fax: 314.726.7501
Practice Areas
Industries
Education
LL.M., Intellectual Property, Washington University in St. Louis
J.D., Washington University in St. Louis
M.S., Biochemistry and Biotechnology, University of Missouri in St. Louis
B.S., Biology, Education College, Seoul National University
Bar & Court Admissions
Missouri
U.S. Supreme Court
U.S. Patent and Trademark Office
Korean Patent Bar